Go Pro
NASDAQ:ONC

BeOne Medicines Q4 2025 Earnings Report

BeOne Medicines logo
$363.73 -4.35 (-1.18%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines EPS Results

Actual EPS
$0.58
Consensus EPS
$1.60
Beat/Miss
Missed by -$1.02
One Year Ago EPS
N/A

BeOne Medicines Revenue Results

Actual Revenue
$1.50 billion
Expected Revenue
$1.45 billion
Beat/Miss
Beat by +$46.29 million
YoY Revenue Growth
N/A

BeOne Medicines Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BeOne Medicines Earnings Headlines

Head to Head Contrast: BeOne Medicines (NASDAQ:ONC) versus GSK (NYSE:GSK)
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More BeOne Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email.

About BeOne Medicines

BeOne Medicines (NASDAQ:ONC) Ltd. is a global biotechnology company focused on the discovery, development and commercialization of medicines for cancer and other serious diseases. The company works across research, clinical development, manufacturing and commercialization, with the goal of expanding access to innovative treatments in markets around the world.

BeOne’s commercial portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat certain B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy approved in multiple markets for several cancer indications. The company also maintains a broad oncology pipeline spanning hematologic cancers and solid tumors, including internally developed and partnered programs.

Founded in 2010 as BeiGene, the company adopted the name BeOne Medicines in 2025 to reflect its global focus. BeOne serves patients and healthcare providers in the United States, China, Europe and other international markets. John V. Oyler is the company’s co-founder, chairman and chief executive officer.

View BeOne Medicines Profile